Pershing Square and other shareholders call for special meeting regarding Allergan hostile bid

23 August 2014
mergers-acquisitions-big

Pershing Square Capital Management, the largest shareholder of Allergan (NYSE: AGN), which is the subject of a $53 billion hostile acquisition approach by Canada’s Valeant Pharmaceuticals International (TSX: VRX; The Pharma Letters passim), announced on Friday that it submitted the required documentation to compel Allergan to call a special meeting of its shareholders.

The written requests, from shareholders owning 31% of Allergan’s shares, exceed the requirements under Allergan’s certificate of incorporation and bylaws to call a special meeting. A substantial majority of the consents were delivered by shareholders who were holders of Allergan prior to the announcement of the proposal by Valeant and Pershing Square, and includes some of the longest-standing and largest shareholders of the company.

Request includes vote on removing the majority of Allergan’s existing directors

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical